MX9702037A - Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno. - Google Patents

Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.

Info

Publication number
MX9702037A
MX9702037A MX9702037A MX9702037A MX9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A
Authority
MX
Mexico
Prior art keywords
tamoxifen
minimizing
analogs
uterotrophic effect
compounds
Prior art date
Application number
MX9702037A
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9702037A publication Critical patent/MX9702037A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion proporciona un miembro para minimizar efecto uterotrofico de compuestos antiestrogénicos de trifenilmetileno no esteroides, cuando tales compuestos se administran para el tratamiento o prevencion de carcinoma de mama, vía la coadministracion de ciertos compuestos naftilo antiestrogénicos. También se proporcionan composiciones farmacéuticas.
MX9702037A 1994-09-20 1995-09-18 Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno. MX9702037A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,904 US5554628A (en) 1994-09-20 1994-09-20 Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
PCT/US1995/012345 WO1996009051A1 (en) 1994-09-20 1995-09-18 A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Publications (1)

Publication Number Publication Date
MX9702037A true MX9702037A (es) 1997-06-28

Family

ID=23195869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702037A MX9702037A (es) 1994-09-20 1995-09-18 Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.

Country Status (16)

Country Link
US (1) US5554628A (es)
EP (1) EP0702961B1 (es)
JP (1) JPH10506111A (es)
KR (1) KR970705999A (es)
AT (1) ATE220919T1 (es)
AU (1) AU692932B2 (es)
CA (1) CA2200205A1 (es)
CZ (1) CZ82097A3 (es)
DE (1) DE69527480D1 (es)
FI (1) FI971155A0 (es)
HU (1) HUT77954A (es)
MX (1) MX9702037A (es)
NO (1) NO971229L (es)
NZ (1) NZ294176A (es)
RU (1) RU2158589C2 (es)
WO (1) WO1996009051A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
JP2001513501A (ja) * 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
EP1709023B1 (en) * 2004-01-22 2009-11-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2012091425A2 (ko) * 2010-12-27 2012-07-05 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
KR101311534B1 (ko) * 2010-12-27 2013-09-25 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
WO2012119010A2 (en) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
US9353132B2 (en) 2012-03-05 2016-05-31 Xavier University Of Louisiana Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65404A0 (en) * 1981-04-03 1982-07-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
EP0702961A3 (en) 1999-11-10
EP0702961B1 (en) 2002-07-24
RU2158589C2 (ru) 2000-11-10
AU3686295A (en) 1996-04-09
JPH10506111A (ja) 1998-06-16
NZ294176A (en) 1999-10-28
KR970705999A (ko) 1997-11-03
FI971155A (fi) 1997-03-19
CZ82097A3 (en) 1997-08-13
NO971229D0 (no) 1997-03-17
ATE220919T1 (de) 2002-08-15
DE69527480D1 (de) 2002-08-29
WO1996009051A1 (en) 1996-03-28
NO971229L (no) 1997-03-17
US5554628A (en) 1996-09-10
CA2200205A1 (en) 1996-03-28
HUT77954A (hu) 1998-12-28
AU692932B2 (en) 1998-06-18
FI971155A0 (fi) 1997-03-19
EP0702961A2 (en) 1996-03-27

Similar Documents

Publication Publication Date Title
HUS1300063I1 (hu) Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
MX9707535A (es) Uso de derivados de vitamina d2 o de vitamina d4 en la preparacion de un farmaco para el tratamiento de hiperparatiroidismo secundario.
DK0589893T3 (da) Anvendelse af et bakteriocin som antimikrobielt middel til fremstilling af et lægemiddel til behandl ing af maveforstyrrelser forbundet med helicobacter pylori
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
HUP0102879A2 (hu) Csontritkulás és klimaxos változások megelőzésére és/vagy kezelésére alkalmas készítmény
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
GEP20002013B (en) Therapeutical Means
SE9704546D0 (sv) Novel compounds
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
YU24403A (sh) Novi retinoidi za terapiju emfizema
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
PL323617A1 (en) Pharmaceutical preparation for treating oestrogen-dependent carcinomas
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
MX163574B (es) Procedimiento para preparar una composicion farmaceutica para inhalacion conteniendo un gangliosido
GB9712966D0 (en) Novel chalcones
GR3031119T3 (en) A pharmaceutical composition comprising a phosphosugar
HUP9901633A2 (hu) Centkromán l-enantiomer alkalmazása gyógyszerkészítmény előállítására, amely alkalmas mellrák kezelésére vagy megelőzésére
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
BG105204A (en) Salts of paroxetine
HUT75942A (en) Neuroprotective chroman compounds and pharmaceutical compositions containing them